Faruqi and Faruqui, LLP Logo
Share this page

Cases: Antitrust Litigation

1 2 3 >
Page 1 of 3 (42 Items)
11
Dec
2013

In re Lidoderm Antitrust Litig., No. 14-2521 (N.D. Cal.)

In the Lidoderm case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo’s 5% lidocaine patch, Lidoderm.  The case alleges that Endo paid its would-be generic competitor, Watson (now known as Actavis) hundreds of millions of dollars to delay entering the market with... READ MORE

02
Dec
2013

In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)

In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim’s combination stroke prevention drug, Aggrenox.  The case alleges that Boehringer paid its would-be generic competitors (Duramed, later known as Barr, and still later known as Teva) to delay launching... READ MORE

23
Jul
2013

In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.)

In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis’s minocycline drug, Solodyn.  The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic competition from entering the market.  The scheme included product reformulations to prevent pharmacists... READ MORE

19
Jun
2013

In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.)

In the Loestrin case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Warner Chilcott’s oral contraceptive drug, Loestrin 24 Fe.  The class alleges that Warner Chilcott and would-be generic competitors entered into a “pay for delay” conspiracy, to prevent purchasers from benefitting from... READ MORE

05
Apr
2013

In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)

In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6).  Faruqi & Faruqi filed the first direct purchaser complaint in this case.  The case alleges that the successive brand... READ MORE

05
Mar
2013

In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)

In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Reckitt Benckiser’s opioid addiction drug, Suboxone.  The proposed class alleges that Reckitt took several actions to suppress competition from generic versions of Suboxone, including reformulating Suboxone into a film (for which... READ MORE

27
Aug
2012

In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)

In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium.  The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, entered into illegal reverse-payment agreements with certain generic manufacturers (namely Ranbaxy,... READ MORE

18
Jul
2012

Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, et al. No. 12-3824 (E. D. Pa.)

In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott’s branded drug, Doryx (delayed-release doxycycline hyclate).  The case alleges that Warner-Chilcott and its licensor, Mayne Pharmaceuticals, to forestall competition from less-expensive generic versions of Doryx, hatched an... READ MORE

23
Jan
2012

In re Skelaxin (Metaxalone) Antitrust Litigation, No. 12-MD-2343 (E.D. Tenn.)

In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represented a pharmaceutical wholesaler and a class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s. The suit alleged that the brand manufacturer (King) and a generic drug... READ MORE

16
Dec
2011

In re Lipitor Antitrust Litigation, No. 12-2389 (PGS/DEA) (D.N.J.)

In this case, nicknamed Lipitor, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s branded blockbuster cholesterol drug Lipitor (atorvastatin calcium), and direct purchasers of generic Lipitor manufactured by Ranbaxy.  The case alleges that Pfizer and its predecessors and affiliates engaged in... READ MORE

14
Dec
2011

In re Effexor XR Antitrust Litigation, No. 11-cv-5479 (D.N.J.)

In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth’s (now Pfizer’s) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules).  The class also includes direct purchasers of generic versions of Effexor XR from Teva, Wyeth’s co-defendant and... READ MORE

09
Dec
2011

Castro et al. v. Sanofi Pasteur, Inc., No. 11-cv-07178 (D. N. J.)

Faruqi & Faruqi represents a proposed class of pediatricians and pediatric practice groups challenging Sanofi-Pasteur, Inc.’s illegal maintenance of a monopoly on the children’s vaccine Menactra in violation of  § 2 of the Sherman Act.  Plaintiffs allege a scheme where Sanofi-Pasteur employs a series of anticompetitive and exclusionary bundling and... READ MORE

02
Nov
2011

Brownson v. Furukawa Electric Co., Ltd. et al, No. 11-14831(E.D. Mich.)

Faruqi & Faruqi represents a proposed class of users of wire harnesses in automobiles against parts manufacturers who pleaded guilty to Department of Justice charges of an conspiracy to fix prices, violating § 1 of the Sherman Act.  Defendants are manufacturers of automotive wiring harnesses.  Defendants drew the attention of... READ MORE

16
Aug
2011

Sotomayor v. Hachette Book Group Inc., et al., No. 11-05707 (S.D.N.Y.)

Faruqi & Faruqi represents a proposed class of e-book purchasers alleging a horizontal conspiracy among book publishers and e-book sellers in the United States to raise, fix, stabilize and maintain retail prices of e-books.

26
Jan
2011

Broadway v. JP Morgan Chase & Co. et al., No. 11-cv-00398 (E.D.N.Y.)

Faruqi & Faruqi represents a proposed class of silver traders that transacted in COMEX silver futures and option contracts.  This lawsuit, against affiliates of JP Morgan and others, challenges defendants’ alleged conspiracy to manipulate prices of COMEX silver futures and options in violation of § 1 of the Sherman Act... READ MORE

30
Jun
2010

In re Iowa Ready-Mixed Concrete Antitrust Litigation, No. C 10-4038 (N.D. Ia.)

Faruqi & Faruqi represented a class of direct purchasers alleging producers and sellers of ready-mixed concrete conspired to fix prices in violation of § 1 of the Sherman Act.  This case settled for $18.5 million in 2011.

07
Jun
2010

In re Prandin Direct Purchaser Antitrust Litigation, No. 10-cv-12141 (E.D. Mich.)

In the Prandin case, Faruqi & Faruqi represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Novo Nordisk’s branded diabetes drug Prandin (repaglinide).   The case alleges that Novo Nordisk engaged in an overarching anticompetitive scheme to block less-expensive generic Prandin competition and thereby force direct purchasers to... READ MORE

30
Apr
2010

Marchese v. Cablevision Systems Corporation, No. 2:10-cv-02190 (D.N.J.)

Marchese v. Cablevision Systems Corporation, No. 2:10-cv-02190 (D.N.J.) (representing a proposed class of direct purchasers of two-way cable services from Cablevision, accusing Cablevision of illegally tying those services to rentals of a Cablevision-supplied set-top box)

31
Mar
2010

Mark S. Wallach, et al. v. Eaton Corp., et al., No. 10-260 (D. Del.)

In the Wallach case, Faruqi & Faruqi, LLP represents a proposed class of purchasers of Class 8 truck transmissions — the types of transmissions used in 18-wheelers.  The case alleges that the dominant manufacturer of the transmissions, Eaton Corporation, and several truck manufacturers, engaged in an exclusive dealing conspiracy that... READ MORE

12
Feb
2010

Isaac Industries, Inc. v. E.I. Dupont De Nemours and Company, et al., No. 10-00323-RDB (D. Md.)

Faruqi & Faruqi represents a proposed class of direct purchasers challenging a conspiracy, by the leading suppliers of Titanium Dioxide in the U.S. and the world,  to fix prices and allocate markets for Titanium Dioxide, in violation of § 1 of the Sherman Act.  Plaintiffs have alleged that defendants E.I.... READ MORE

1 2 3 >
Page 1 of 3 (42 Items)